3.7253

4.27% -0.1747

Diamedica Therapeutics Inc (DMAC)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Diamedica Therapeutics Inc stock is traded at $3.7253, with a volume of 53,826. It is down -4.27% in the last 24 hours and down -6.20% over the past month. DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Previous Close:

$3.90

Open:

$3.85

24h Volume:

53,826

Relative Volume:

0.55

Market Cap:

$175.39M

Revenue:

Net Income/Loss:

$-19.90M

P/E Ratio:

-7.0289

EPS:

-0.53

Net Cash Flow:

$-19.80M

1W Performance:

-9.82%

1M Performance:

-6.20%

6M Performance:

-30.61%

1Y Performance:

+58.87%

1-Day Range:

$3.70

$3.94

1-Week Range:

$3.705

$4.275

52-Week Range:

$2.14

$6.8184

Diamedica Therapeutics Inc Stock (DMAC) Company Profile

Name

Diamedica Therapeutics Inc

Sector

Healthcare (1174)

Industry

Biotechnology (661)

Phone

(763) 496-5454

Address

301 CARLSON PARKWAY, MINNEAPOLIS, MN

Employee

Twitter

@diamedica

Next Earnings Date

2025-03-17

Latest SEC Filings

DMAC's Discussions on Twitter

Compare DMAC with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DMAC Diamedica Therapeutics Inc	3.70	175.39M	0	-19.90M	-19.80M	-0.53
VRTX Vertex Pharmaceuticals Inc	459.07	113.97B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	522.76	52.15B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	306.63	40.16B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	581.05	35.45B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	271.38	27.80B	3.81B	-644.79M	-669.77M	-6.24

Diamedica Therapeutics Inc Stock (DMAC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-07-24	Initiated	H.C. Wainwright	Buy
Apr-24-24	Resumed	Craig Hallum	Buy
Jun-22-23	Upgrade	Oppenheimer	Perform → Outperform
Apr-09-21	Initiated	Oppenheimer	Outperform
Feb-17-21	Initiated	ROTH Capital	Buy
Oct-30-20	Initiated	Guggenheim	Buy
Jul-08-20	Initiated	Maxim Group	Buy
Apr-30-19	Initiated	Dougherty & Company	Buy
Mar-05-19	Initiated	Lake Street	Buy

View All

Diamedica Therapeutics Inc Stock (DMAC) Latest News

Jun 10, 2025

Millennium Management LLC Increases Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World

Jun 10, 2025

Jun 05, 2025

42,212 Shares in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Purchased by Jane Street Group LLC - Defense World

Jun 05, 2025

Jun 04, 2025

Can DiaMedica Deliver A Breakthrough In Preeclampsia Treatment? - RTTNews

Jun 04, 2025

Short Interest in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Increases By 38.3% - Defense World

Jun 04, 2025

May 30, 2025

Lake Street Keeps Their Buy Rating on Diamedica Therapeutics (DMAC) - The Globe and Mail

May 30, 2025

Northern Trust Corp Has $978,000 Holdings in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) - Defense World

May 30, 2025

DMAC: HC Wainwright & Co. Reiterates Buy Rating with $10 Price T - GuruFocus

May 30, 2025

DiaMedica Therapeutics’ (DMAC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

May 30, 2025

May 29, 2025

H.C. Wainwright holds DiaMedica stock Buy rating, $10 target - Investing.com

May 29, 2025

H.C. Wainwright holds DiaMedica stock Buy rating, $10 target By Investing.com - Investing.com India

May 29, 2025

May 28, 2025

Transcript : DiaMedica Therapeutics Inc.Special Call - marketscreener.com

May 28, 2025

With 39% ownership, DiaMedica Therapeutics Inc. (NASDAQ:DMAC) insiders have a lot riding on the company's future - Yahoo Finance

May 28, 2025

May 22, 2025

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025 - BioSpace

May 22, 2025

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025 | DMAC Stock News - GuruFocus

May 22, 2025

May 20, 2025

14,581 Shares in DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Purchased by Balyasny Asset Management L.P. - Defense World

May 20, 2025

May 19, 2025

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on D - GuruFocus

May 19, 2025

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia - Business Wire

May 19, 2025

Research Analysts Offer Predictions for DMAC FY2025 Earnings - Defense World

May 19, 2025

May 18, 2025

Equities Analysts Offer Predictions for DMAC FY2029 Earnings - Defense World

May 18, 2025

May 17, 2025

DiaMedica targets preeclampsia Phase 2 dose selection and ReMEDy2 interim analysis in H1 2026 as enrollment momentum builds - MSN

May 17, 2025

May 16, 2025

Analysts Offer Insights on Healthcare Companies: Organon (OGN), Diamedica Therapeutics (DMAC) and Nkarta (NKTX) - The Globe and Mail

May 16, 2025

Craig-Hallum Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC) - The Globe and Mail

May 16, 2025

DiaMedica Therapeutics reports annual meeting results By Investing.com - Investing.com Nigeria

May 16, 2025

May 15, 2025

DiaMedica Therapeutics reports annual meeting results - Investing.com

May 15, 2025

DiaMedica Elects Directors at Annual Meeting - TipRanks

May 15, 2025

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q1 2025 Earnings Call Transcript - Insider Monkey

May 15, 2025